A prospective harmonized multicenter DTI study of cerebral white matter degeneration in ALS.
Adult
Aged
Amyotrophic Lateral Sclerosis
/ diagnostic imaging
Cerebral Cortex
/ diagnostic imaging
Diffusion Tensor Imaging
Disease Progression
Female
Humans
Image Interpretation, Computer-Assisted
/ methods
Longitudinal Studies
Male
Middle Aged
Nerve Degeneration
/ diagnostic imaging
Neuroimaging
/ methods
Prospective Studies
Pyramidal Tracts
/ diagnostic imaging
White Matter
/ diagnostic imaging
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
25 08 2020
25 08 2020
Historique:
received:
02
12
2019
accepted:
17
02
2020
pubmed:
11
7
2020
medline:
22
10
2020
entrez:
11
7
2020
Statut:
ppublish
Résumé
To evaluate progressive white matter (WM) degeneration in amyotrophic lateral sclerosis (ALS). Sixty-six patients with ALS and 43 healthy controls were enrolled in a prospective, longitudinal, multicenter study in the Canadian ALS Neuroimaging Consortium (CALSNIC). Participants underwent a harmonized neuroimaging protocol across 4 centers that included diffusion tensor imaging (DTI) for assessment of WM integrity. Three visits were accompanied by clinical assessments of disability (ALS Functional Rating Scale-Revised [ALSFRS-R]) and upper motor neuron (UMN) function. Voxel-wise whole-brain and quantitative tract-wise DTI assessments were done at baseline and longitudinally. Correction for site variance incorporated data from healthy controls and from healthy volunteers who underwent the DTI protocol at each center. Patients with ALS had a mean progressive decline in fractional anisotropy (FA) of the corticospinal tract (CST) and frontal lobes. Tract-wise analysis revealed reduced FA in the CST, corticopontine/corticorubral tract, and corticostriatal tract. CST FA correlated with UMN function, and frontal lobe FA correlated with the ALSFRS-R score. A progressive decline in CST FA correlated with a decline in the ALSFRS-R score and worsening UMN signs. Patients with fast vs slow progression had a greater reduction in FA of the CST and upper frontal lobe. Progressive WM degeneration in ALS is most prominent in the CST and frontal lobes and, to a lesser degree, in the corticopontine/corticorubral tracts and corticostriatal pathways. With the use of a harmonized imaging protocol and incorporation of analytic methods to address site-related variances, this study is an important milestone toward developing DTI biomarkers for cerebral degeneration in ALS. NCT02405182.
Identifiants
pubmed: 32646955
pii: WNL.0000000000010235
doi: 10.1212/WNL.0000000000010235
pmc: PMC7668555
doi:
Banques de données
ClinicalTrials.gov
['NCT02405182']
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e943-e952Subventions
Organisme : CIHR
Pays : Canada
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 American Academy of Neurology.
Références
Amyotroph Lateral Scler. 2011 Nov;12(6):421-9
pubmed: 21745124
Amyotroph Lateral Scler Frontotemporal Degener. 2015 Mar;16(1-2):92-101
pubmed: 25574564
J Neurol Neurosurg Psychiatry. 2012 Apr;83(4):383-8
pubmed: 21965521
Neuroimage Clin. 2017 Jan 24;14:269-276
pubmed: 28203530
Neuroimage. 2010 Jul 15;51(4):1384-94
pubmed: 20338248
Magn Reson Imaging. 2009 Apr;27(3):324-34
pubmed: 18701228
Cortex. 2018 Apr;101:163-171
pubmed: 29477906
Hum Brain Mapp. 2010 Nov;31(11):1727-40
pubmed: 20336652
Brain. 2014 Sep;137(Pt 9):2546-55
pubmed: 24951638
Front Hum Neurosci. 2017 Dec 05;11:567
pubmed: 29259550
Amyotroph Lateral Scler. 2009 Oct-Dec;10(5-6):310-23
pubmed: 19922118
Nat Rev Neurosci. 2002 Mar;3(3):243-9
pubmed: 11994756
Neuroimage. 2012 Apr 2;60(2):1127-38
pubmed: 22227883
Ann Neurol. 2013 Jul;74(1):20-38
pubmed: 23686809
Neuroimage. 2002 Apr;15(4):870-8
pubmed: 11906227
J Neurol Sci. 1999 Oct 31;169(1-2):13-21
pubmed: 10540002
J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):374-381
pubmed: 29101254
Neurology. 2019 Apr 2;92(14):e1610-e1623
pubmed: 30850440
Front Neurosci. 2018 Sep 26;12:655
pubmed: 30319338
Arch Neurol. 2012 Nov;69(11):1493-9
pubmed: 22910997
Expert Rev Neurother. 2016;16(3):295-306
pubmed: 26807776
J Neurol Neurosurg Psychiatry. 2016 Jun;87(6):570-9
pubmed: 26746186
BMC Neurosci. 2012 Nov 08;13:141
pubmed: 23134591
Curr Opin Neurol. 2019 Oct;32(5):740-746
pubmed: 31335337
Biomark Med. 2012 Jun;6(3):319-37
pubmed: 22731907
Ann Clin Transl Neurol. 2018 Sep 23;5(11):1350-1361
pubmed: 30480029
PLoS Curr. 2014 Mar 21;6:
pubmed: 24672743
Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(7-8):524-9
pubmed: 26402254
J Vis Exp. 2013 Jul 28;(77):
pubmed: 23928996
Neurobiol Aging. 2005 Aug-Sep;26(8):1215-27
pubmed: 15917106
Phys Med Biol. 2007 Mar 21;52(6):N99-109
pubmed: 17327646
Clin Neuropsychol. 2005 Feb;19(1):105-20
pubmed: 15814482
AJNR Am J Neuroradiol. 2014 Feb;35(2):304-10
pubmed: 24113470
Neuroimage Clin. 2016 Mar 16;11:408-414
pubmed: 27104135
PLoS One. 2014 Aug 21;9(8):e105753
pubmed: 25144708
Neurotherapeutics. 2017 Jan;14(1):11-23
pubmed: 27752938
Magn Reson Med Sci. 2004 Apr 1;3(1):11-7
pubmed: 16093615
Cereb Cortex. 2015 Jun;25(6):1477-89
pubmed: 24343892
Amyotroph Lateral Scler. 2012 May;13(3):254-64
pubmed: 22409361
Lancet Neurol. 2009 Jan;8(1):94-109
pubmed: 19081518
Brain. 2014 Jun;137(Pt 6):1733-40
pubmed: 24736303
Biomed Eng Online. 2007 Nov 09;6:42
pubmed: 17996104